BioCentriq and Cytiva Awarded NIIMBL Funding to Accelerate Bringing Gene Therapies to Market

Newark, New Jersey – June 27, 2023 – BioCentriq and Cytiva announced today that they have received funding from NIIMBL to develop a viral and exotoxin clearance platform for adeno-associated virus (AAV) manufacturing. The goal of this project is to establish new standards and advance gene therapies by enhancing AAV manufacturing processes.

The collaboration between Cytiva and BioCentriq showcases the importance of partnerships in addressing industry challenges and promoting open innovation, and BioCentriq is thrilled to have been selected to work on this project and collaborate with Cytiva.

With the potential to achieve scalable viral clearance, enhance manufacturing efficiency, and reduce costs, this project has the potential to spark significant advancements to the genomic medicine industry.

Read the full press release here.

Cytiva and BioCentriq logos together over background of two people working in a clean room